Core Insights - Avacta Therapeutics has presented preclinical data on its first-in-class dual payload peptide drug conjugate, AVA6207, which aims to enhance tumor control and overcome resistance mechanisms in cancer therapy [1][2]. Company Overview - Avacta is a clinical stage biopharmaceutical company focused on developing the pre|CISION platform, which enables targeted delivery of oncology drugs through peptide drug conjugates (PDCs) [13]. Technology and Innovation - The dual payload technology allows for the simultaneous delivery of two distinct therapeutic agents to the tumor microenvironment via a single fibroblast activation protein (FAP)-mediated cleavage event, addressing critical challenges in cancer treatment [2][3]. - The pre|CISION platform has demonstrated a tumor-to-plasma payload concentration of 100:1 with reduced off-target toxicities, even at doses up to approximately four times that of conventional doxorubicin [5]. Preclinical Findings - The dual payload technology showed robust FAP-selective delivery and potent anti-tumor activity, with IC50 values ranging from 2-9 nM in the presence of FAP, indicating excellent tumor selectivity [6]. - The technology confirmed dual mechanism biomarker modulation, with specific biomarkers being affected only in the presence of FAP, validating the effectiveness of the dual payload approach [6][7]. - Enhanced synergistic activity was observed, with FAP-dependent tumor cell killing being 4-5 times greater compared to exatecan alone, effectively addressing known resistance pathways [7]. Market Potential - The pre|CISION platform targets a large addressable market, potentially impacting 90% of solid tumors, and offers advantages over traditional antibody drug conjugates (ADCs) such as better tumor penetration and reduced toxicity [7].